Advertisement

Neuroimaging Findings in Patients with Medication Overuse Headache

  • Tzu-Hsien Lai
  • Shuu-Jiun WangEmail author
Chronic Daily Headache (SJ Wang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Chronic Daily Headache

Abstract

Medication overuse headache (MOH) is a secondary headache syndrome defined as the deterioration of the headache associated with the overuse of analgesics. The prevalence of MOH is 1–2% in the general population and even up to 50% in special clinics. Overuse of abortive medications is highly associated with chronic daily headaches and also a known risk factor for headache evolution. Possible mechanisms include neural plasticity changes such as sensitization and defective endogenous pain inhibition. Psychological studies have suggested dependence, even addiction, in patients with MOH. Neuroimaging studies have provided valuable information concerning MOH pathophysiology. Magnetic resonance imaging analyzed by voxel-based morphometry showed gray matter volume changes in brain areas participating the pain modulations. Changes of brain function at similar areas have been revealed by positron emission tomography and functional magnetic resonance imaging studies. Many of these changes were correlated with either headache and/or analgesics parameters such as frequency and duration. These changes are typically reversible after successful treatment. Though the cause or consequence debate remains unsettled, we are more in favor of these findings as maladaptive changes to the frequent headaches or medication overuse. Of these brain areas involved in MOH, orbitofrontal cortex is of interest in several ways. In an early positron emission tomography study, the hypometabolism persists after successful treatment which implied a causal role. The following morphological studies showed the orbitofrontal cortex volume could predict treatment responses. Functional magnetic resonance imaging studies, task positive and also resting-state ones, also reported changes within the mesocorticolimbic dopamine system, also known as reward system. Important brain areas of this system include ventral tegmental area, striatum, and orbitofrontal cortex. The system plays an important role in decision-making, dependence, and addiction, as implicated in psychological studies of MOH. Further studies on neuromodulation of this system may be considered in the treatment of MOH.

Keywords

Magnetic resonance imaging Medication overuse headache Positron emission tomography 

Notes

Funding Information

This study was supported in part by grants from the Taipei Veterans General Hospital (V106C-106, VGHUST105-G7-1-1, V105C-127, V105D9-001-MY2-2, V105E9-001-MY2-1, VTA105-V1-1-1), Ministry of Science and Technology of Taiwan (MOST 106-2321-B-010-009-, MOST 10-2314-B-010-015-MY2, and MOST 103-2321-B-010-017-), Academia Sinica (Grant No. IBMS-BM10601010026, IBMS-CRC103-P04), Brain Research Center, National Yang-Ming University, Ministry of Health and Welfare, Taiwan (MOHW 103-TDU-B-211-113-003, MOHW 104-TDU-B-211-113-003, MOHW 105-TDU-B-211-113-003), National Yang-Ming University–Far Eastern Memorial Hospital Joint Research Program (NYMU-FEMH 105FN10, NYMU-FEMH 106DN10), Far Eastern Memorial Hospital (FEMH-2016-C-023, FEMH-2017-D-004), and a grant from the Ministry of Education, Aim for the Top University Plan.

Compliance with Ethical Standards

Conflict of Interest

Tzu-Hsien Lai declares no conflict of interest. Dr. Wang reports personal fees from Eli-Lilly, personal fees from Daiichi-Sankyo, personal fees from Pfizer, Taiwan, personal fees from Bayer, and personal fees from Eisai, all outside of the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Peters GA, Horton BT. Headache; with special reference to the excessive use of ergotamine tartrate and dihydroergotamine. J Lab Clin Med. 1950;36(6):972–3.PubMedGoogle Scholar
  2. 2.
    Kudrow L. Paradoxical effects of frequent analgesic use. Adv Neurol. 1982;33:335–41.PubMedGoogle Scholar
  3. 3.
    Saper JR, da Silva AN. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs. 2013;27(11):867–77.  https://doi.org/10.1007/s40263-013-0081-y.CrossRefPubMedGoogle Scholar
  4. 4.
    Headache Classification Subcommittee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.  https://doi.org/10.1177/0333102413485658.CrossRefGoogle Scholar
  5. 5.
    Siberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near-daily headaches: proposed revisions to the HIS criteria. Headache. 1994;34(1):1–7.  https://doi.org/10.1111/j.1526-4610.1994.hed3401001.x.CrossRefPubMedGoogle Scholar
  6. 6.
    Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996;47(4):871–5.  https://doi.org/10.1212/WNL.47.4.871.CrossRefPubMedGoogle Scholar
  7. 7.
    Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210.  https://doi.org/10.1111/j.1468-2982.2007.01288.x.CrossRefPubMedGoogle Scholar
  8. 8.
    Stark RJ, Ravishankar K, Siow HC, Lee KS, Pepperle R, Wang SJ. Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review. Cephalalgia. 2013;33(4):266–83.  https://doi.org/10.1177/0333102412468677.CrossRefPubMedGoogle Scholar
  9. 9.
    Munksgaard SB, Jensen RH. Medication overuse headache. Headache. 2014;54(7):1251–7.  https://doi.org/10.1111/head.12408.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang SJ, Fuh JL, Lu S, Juang K. Chronic daily headache in adolescents: prevalence, impact, and medication overuse. Neurology. 2006;66(2):193–7.  https://doi.org/10.1212/01.wnl.0000183555.54305.fd.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang SJ, Fuh JL, Lu S, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology. 2000;54(2):314–9.  https://doi.org/10.1212/WNL.54.2.314.CrossRefPubMedGoogle Scholar
  12. 12.
    • Lai TH, Protsenko E, Cheng YC, Loggia ML, Coppola G, Chen WT. Neural plasticity in common forms of chronic headaches. Neural Plast. 2015;2015:205985. This article thoroughly discussed neural plasticity changes related to various types of important headaches, including medication overuse headache. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Johnson JL, Hutchinson MR, Williams DB, Rolan P. Medication overuse headache and opioid-induced hyperalgesia: a review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia. 2013;33(1):52–64.  https://doi.org/10.1177/0333102412467512.CrossRefPubMedGoogle Scholar
  14. 14.
    De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol. 2010;67(3):325–37.  https://doi.org/10.1002/ana.21897.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Fuh JL, Wang SJ. Dependent behavior in patients with medication-overuse headache. Curr Pain Headache Rep. 2012;16(1):73–9.  https://doi.org/10.1007/s11916-011-0240-0.CrossRefPubMedGoogle Scholar
  16. 16.
    Schmidt-Wilcke T, Leinisch E, Straube A, et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005;65:1485–6.CrossRefGoogle Scholar
  17. 17.
    Riederer F, Marti M, Luechinger R, Lanzenberger R, von Meyenburg J, Gantenbein AR, et al. Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety. World J Biol Psychiatry. 2012;13(7):517–25.  https://doi.org/10.3109/15622975.2012.665175.CrossRefPubMedGoogle Scholar
  18. 18.
    • Riederer F, Gantenbein AR, Marti M, Luechinger R, Kollias S, Sándor PS. Decrease of gray matter volume in the midbrain is associated with treatment response in medication-overuse headache: possible influence of orbitofrontal cortex. J Neurosci. 2013;33:15343–9. The study confirmed the reversibility of gray matter volumes after treatment of medication overuse headache and pointed out the orbitofrontal cortex volume in predicting the treatment response. CrossRefPubMedGoogle Scholar
  19. 19.
    Chanraud S, Di Scala G, Dilharreguy B, Schoenen J, Allard M, Radat F. Brain functional connectivity and morphology changes in medication-overuse headache: clue for dependence-related processes. Cephalalgia. 2014;34(8):605–15.  https://doi.org/10.1177/0333102413519514.CrossRefPubMedGoogle Scholar
  20. 20.
    Lai TH, Chou KH, Fuh JL, Lee PL, Kung YC, Lin CP, et al. Gray matter changes related to medication overuse in patients with chronic migraine. Cephalalgia. 2016;36(14):1324–33.  https://doi.org/10.1177/0333102416630593.CrossRefPubMedGoogle Scholar
  21. 21.
    Zheng Z, Xiao Z, Shi X, Ding M, Di W, Qi W, et al. White matter lesions in chronic migraine with medication overuse headache: a cross-sectional MRI study. J Neurol. 2014;261(4):784–90.  https://doi.org/10.1007/s00415-014-7267-1.CrossRefPubMedGoogle Scholar
  22. 22.
    Michels L, Christidi F, Steiger VR, et al. Pain modulation is affected differently in medication-overuse headache and chronic myofascial pain—a multimodal MRI study. Cephalalgia. 2017;37(8):764–79.Google Scholar
  23. 23.
    • Fumal A, Laureys SD, Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain. 2006;129:543–50. The study first showed the persistent hypometabolism of orbitofrontal cortex indicating the causal role of this brain area in medication overuse headache. CrossRefPubMedGoogle Scholar
  24. 24.
    Ferraro S, Grazzi L, Muffatti R, Nava S, Ghielmetti F, Bertolino N, et al. In medication-overuse headache, fMRI shows long-lasting dysfunction in midbrain areas. Headache. 2012;52(10):1520–34.  https://doi.org/10.1111/j.1526-4610.2012.02276.x.CrossRefPubMedGoogle Scholar
  25. 25.
    Ferraro S, Grazzi L, Mandelli ML, Aquino D, di Fiore D, Usai S, et al. Pain processing in medication overuse headache: a functional magnetic resonance imaging (fMRI) study. Pain Med. 2012;13(2):255–62.  https://doi.org/10.1111/j.1526-4637.2011.01183.x.CrossRefPubMedGoogle Scholar
  26. 26.
    Torta DM, Costa T, Luda E, Barisone MG, Palmisano P, Duca S, et al. Nucleus accumbens functional connectivity discriminates medication-overuse headache. Neuroimage Clin. 2016;11:686–93.  https://doi.org/10.1016/j.nicl.2016.05.007.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lai TH, Fuh JL, Lirng JF, Lin CP, Wang SJ. Brainstem 1H-MR spectroscopy in episodic and chronic migraine. J Headache Pain. 2012;13(8):645–51.  https://doi.org/10.1007/s10194-012-0491-0.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bingel U, Tracey I. Imaging CNS modulation of pain in humans. Physiology. 2008;23(6):371–80.  https://doi.org/10.1152/physiol.00024.2008.CrossRefPubMedGoogle Scholar
  29. 29.
    Legrain V, Iannetti GD, Plaghki L, Mouraux A. The pain matrix reloaded: a salience detection system for the body. Prog Neurobiol. 2011;93(1):111–24.  https://doi.org/10.1016/j.pneurobio.2010.10.005.CrossRefPubMedGoogle Scholar
  30. 30.
    Hougaard A, Amin FM, Ashina M. Migraine and structural abnormalities in the brain. Curr Opin Neurol. 2014;27(3):309–14.  https://doi.org/10.1097/WCO.0000000000000086.CrossRefPubMedGoogle Scholar
  31. 31.
    Reyngoudt H, Achten E, Paemeleire K. Magnetic resonance spectroscopy in migraine: what have we learned so far? Cephalalgia. 2012;32(11):845–59.  https://doi.org/10.1177/0333102412452048.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Neurology, School of MedicineNational Yang-Ming UniversityTaipeiTaiwan
  2. 2.Department of NeurologyFar Eastern Memorial HospitalNew TaipeiTaiwan
  3. 3.Department of Neurology, Neurological InstituteTaipei Veterans General HospitalTaipeiTaiwan

Personalised recommendations